Chengdu Haibowei

Chengdu Haibowei is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the development of innovative small molecule therapeutics. Established in 2019, the company focuses on addressing unmet medical needs in oncology, central nervous system disorders, and inflammatory diseases. Its proprietary high-efficiency drug discovery platform enables the rapid identification and optimization of candidates with improved safety and efficacy profiles. The lead program, HBW-3220, is a next-generation reversible BTK inhibitor currently in clinical development for B-cell malignancies. Additionally, the company is advancing a diverse pipeline including Nav1.8 inhibitors for pain and TYK2 inhibitors for autoimmune conditions. Haibowei aims to establish itself as a leader in the global pharmaceutical market through strategic collaborations and internal innovation.